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COST-EFFECTIVENESS OF BORTEZOMIB (VELCADE) FOR
RELAPSED AND REFRACTORY MULTIPLE MYELOMA
Bagust A1, Haycox A1, Mujica-Mota R1, Dhawan R2, Dubois D3
1University of Liverpool, Liverpool, UK; 2Johnson & Johnson
Pharmaceutical Services LLC, Raritan, NJ, USA; 3Johnson & Johnson
Pharmaceutical Services LLC, Beerse, Belgium
OBJECTIVES: Currently, no active third-line treatment exists for
patients previously treated for multiple myeloma, who fail to
respond to conventional chemotherapy. A model was developed
to evaluate the costs and beneﬁts of a new proteasome inhibitor,
VELCADE, relative to best supportive care. METHODS: A two-
part mathematical model of survival was applied to individual
patient data from the SUMMIT1 trial, a multi-center phase 2,
single arm trial of adult patients with a life expectancy of more
than three months; in the ﬁrst part the time to disease progres-
sion for patients was estimated; the time from disease progres-
sion till death was estimated in the second part. Several survival
estimation techniques were applied. Resource use data from
SUMMIT were used to estimate costs from the perspective of the
NHS in the UK for VELCADE administration, hospital care,
concomitant medications and diagnostic tests and surgical pro-
cedures on an individual patient basis. RESULTS: By delaying
the rate at which disease progresses, VELCADE produces sur-
vival gains relative to Best Supportive Care that range between
7.75 to 12.09 months of life depending on the assumed survival
proﬁle. Additional costs (2003 prices) of the novel agent were
£17,290 without accounting for additional costs incurred during
the extended period of survival or £24,121 if such costs are
included. Combining these results with various survival estima-
tions yields an incremental cost-effectiveness ratio (ICER) 
for VELCADE in the range of £17,161–£33,539 per life year
gained. CONCLUSION: VELCADE has been licensed in Europe
and hence information with regard to its clinical and cost-
effectiveness is timely. The range of ICER estimates obtained
(£17,000–£33,000 per additional life year) demonstrate cost-
effectiveness of VELCADE as compared with Best Supportive
Care. These ICER estimates compare favourably to other salvage
therapies currently in widespread use throughout the UK.
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COST-UTILITY ANALYSIS OF FULVESTRANT VERSUS
EXEMESTANE IN THE SECOND LINE TREATMENT OF
POSTMENOPAUSAL WOMEN WITH ADVANCED BREAST
CANCER
Ryan J1, Hirsch M2, Knight H1
1Mapi Values Ltd, Macclesﬁeld, Cheshire, UK; 2AstraZeneca UK Ltd,
Macclesﬁeld, Cheshire, UK
OBJECTIVE: To assess the cost-utility of fulvestrant (Faslodex)
as a replacement for exemestane (Aromasin) in the second line
treatment of postmenopausal women with advanced breast
cancer (ABC) in England. METHODS: A Markov model was
developed allowing up to three separate lines of treatment. In the
scenario studied, patients received fulvestrant or exemestane, fol-
lowed by megestrol acetate and then a ﬁnal palliative care
package. The clinical pathways and resource use assumptions
were based on a survey of UK oncologists. The analysis was from
the perspective of the UK National Health Service (NHS) and
estimated the total cost and beneﬁts, including quality adjusted
life years (QALYs), of two patient cohorts. Clinical evidence was
taken from published clinical trials. Unit costs were taken from
nationally published sources and reported in year 2003 prices.
Treatment each month comprised of drug therapy plus other
care, including treatment of adverse events and health care pro-
fessional visits. Costs varied depending on the health state the
patients were in during any month. The time horizon of the
model was 11 years. All costs and QALYs within the model were
discounted at 3.5%. RESULTS: The model was run with a
cohort of 100 patients. When compared against exemestane in
second line treatment, the 100 patients on fulvestrant gained an
extra 8.1 QALYs for an additional cost of £240,705 giving an
incremental cost-effectiveness ratio (ICER) of £29,641 per
QALY. CONCLUSIONS: Fulvestrant is likely to produce addi-
tional beneﬁts compared with exemestane at an acceptable addi-
tional cost, illustrated by the ICER of £29,641 per QALY. The
health beneﬁt gain from fulvestrant was driven primarily by both
a higher proportion of responders and longer time on second line
treatment. The ﬁndings suggest that fulvestrant is a cost-
effective second line option to the NHS in the UK.
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COST-UTILITY ANALYSIS OF ANASTROZOLE VERSUS
TAMOXIFEN AS ADJUVANT THERAPY IN POSTMENOPAUSAL
WOMEN WITH EARLY BREAST CANCER (EBC): A UK
NATIONAL HEALTH SERVICE (NHS) PERSPECTIVE
Brown R1, Benedict A1, Mansel RE2
1MEDTAP International Inc, London, UK; 2University of Wales College
of Medicine, Cardiff, UK
OBJECTIVES: This study estimated the incremental cost per
quality adjusted life year (QALY) gained for anastrozole com-
pared with tamoxifen from the UK NHS perspective, based upon
ATAC trial data (Cancer 2003;98:1802–10). In this trial, anas-
trozole demonstrated superior efﬁcacy and tolerability versus
tamoxifen. Cost-effectiveness analysis found that over 25 years
anastrozole had an incremental cost-effectiveness ratio (ICER) of
GBP11,747 per life-year gained (LYG) among the clinically rele-
vant population of patients with hormone receptor-positive
(HR+) EBC. The model was expanded to include patient utilities
to meet NICE and Scottish Medicines Committee preferences for
cost-utility analysis and to facilitate comparisons across disease
areas. METHODS: Patient utilities were elicited from 23 EBC
patients on adjuvant hormonal therapy. Using the standard
gamble technique, health states relating to adverse events reported
in ATAC and breast cancer disease states were compiled and
reviewed by clinicians. Utility values were incorporated into the
cost-effectiveness model projecting outcomes for anastrozole and
tamoxifen to 25 years, based on probability of side effects (ATAC
safety data) and time in a particular health state. All parameters
(including utilities) were varied in sensitivity analyses. QALYs and
unadjusted LYG were compared with cost outcomes. RESULTS:
Patients’ valuation of the different health states ranged from 0.71
to 0.99. Differences between incremental LYG and QALYs for
anastrozole and tamoxifen were similar (0.3). The discounted
ICER of anastrozole compared with tamoxifen was GBP11,506
per QALY gained (95% CI: GBP1771–GBP22,491). CONCLU-
SIONS: The incorporation of mean-adjusted utility values
resulted in only minor improvement in the ICER in favour of
anastrozole. Furthermore, sensitivity analysis showed that the
ICER was robust to changes in utility scores and that the great-
est impact on the ICER remains the improved disease-free sur-
vival with anastrozole. Anastrozole provides QALY gains at
acceptable costs compared with tamoxifen in the adjuvant treat-
ment of postmenopausal women with HR+ EBC.
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HOSPITALIZATION COSTS OF PATIENTS WITH INFECTIONS
WHO HAVE LUNG CANCER OR NEUTROPENIA IN
SWEDEN—A RETROSPECTIVE DATABASE STUDY
Myren KJ
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OBJECTIVE: All chemotherapy regimens are associated with
some degree of adverse events. The more severe adverse events
require hospitalization and may be associated with high costs.
One adverse event that may be serious is infection and in par-
ticular infection because of neutropenia. The objective of this
study was to retrospectively assess the hospitalization costs of
infections and neutropenia in cancer patients. METHODS: Indi-
vidual patient data on costs, diagnoses, and length of stay were
collected from the largest cost per patient inpatient database in
Sweden. The time period was January 1999 to January 2000.
The hospitals included in the database all have a detailed
resource tracking and cost assignment system for determining the
individual cost per stay. All non-surgical patients who had the
combination of a cancer ICD-10 (C000 to C997) and an infec-
tion diagnosis recorded in the database were selected. Patients
who also had a neutropenia (D709) diagnosis recorded were
selected and studied as a subsample of the whole sample.
RESULTS: There were 2378 patients who had a cancer and an
infection diagnosis. Their mean cost was (SEK) 69,700 and the
mean length of stay was 12.3 days. The average age was 62 years
and there were 59% women. Patients with a principal cancer
diagnosis had greater costs than patients with a secondary cancer
diagnosis, 85,500 versus 50,600. Out of the 2378 patients there
were 52 who had both neutropenia and an infection. Their mean
age was 55 years. There were slightly more women than men,
54%. The mean cost was (SEK) 77,900 and the mean length of
stay was 12.9 days. CONCLUSIONS: The hospitalization costs
of infections and neutropenia in cancer patients are signiﬁcant.
When assessing the costs of chemotherapy treatments, not only
pharmaceutical costs, but also costs of adverse events should be
included.
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THE LIFETIME COST OF GEFITINIB (“IRESSA”) IN TREATING
PATIENTS WITH NON-SMALL-CELL LUNG CANCER (NSCLC)
Haiderali A1, Chin W2
1AstraZeneca Canada Inc, Mississauga, Ontario, Canada; 2Axia
Research Inc, Salt Lake City, UT, USA
OBJECTIVES: The objective of this study was to determine the
lifetime cost of treating NSCLC patients with geﬁtinib. NSCLC
is a fatal malignancy that responds poorly to chemotherapy. Best
Supportive Care (BSC) is frequently offered when management
with anticancer treatments is not feasible. Geﬁtinib (“Iressa”) is
the ﬁrst epidermal growth factor receptor tyrosine kinase
inhibitor approved for the treatment of patients with locally
advanced or metastatic NSCLC. METHODS: Duration of geﬁ-
tinib treatment was estimated by the time to progression in
IDEAL 2, a phase II clinical trial involving patients with
advanced or metastatic NSCLC who had previously received
platinum-based chemotherapy. Post progression, patients were
assumed to receive BSC. Resource utilization was estimated from
the clinical trial. The cost of BSC following chemotherapy was
provided by CancerCare Manitoba. Costs were expressed in
Canadian dollars (2003). RESULTS: Patients (n = 102) received
geﬁtinib 250mg daily. Over 40% of patients achieved a complete
response, partial response or stable disease, and clinically signif-
icant improvement in disease-related symptoms occurred in most
of these patients. Median time to progression was 1.9 months.
The median survival time was 7 months. The tolerability proﬁle
of geﬁtinib was mild and there was a low incidence of grade 3/4
adverse reactions. The lifetime cost of treating a patient with geﬁ-
tinib plus BSC was estimated at $14,496. In sensitivity analyses,
that lifetime cost ranged from $13,822 up to $24,915. CONL-
CUSIONS: The lifetime cost to treat a patient with geﬁtinib plus
BSC was $14,496, which is comparable to costs for other
chemotherapies for NSCLC. For example, the lifetime cost of
second-line docetaxel was $17,739 (1999 dollars [$19,389 in
2003 dollars]) and for other chemotherapies, lifetime costs
ranged from $24,828 up to $41,178 (1995 dollars [$29,059 to
$48,196 in 2003 dollars]). “Iressa” is a trademark of the
AstraZeneca group of companies.
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COST-EFFECTIVENESS ANALYSIS OF ORAL IBANDRONATE
VERSUS IV ZOLEDRONIC ACID OR IV GENERIC
PAMIDRONATE FOR BONE METASTASES FROM BREAST
CANCER IN PATIENTS RECEIVING ORAL HORMONAL
THERAPY IN THE UK
De Cock E1, Hutton J1, Barrett-Lee P2, Canney P3, Body JJ4,
Neary M5, Lewis GJ6
1MEDTAP International Inc, London, UK; 2Velindre Cancer Centre,
Cardiff, UK; 3Western Hospital, Glasgow, UK; 4Université Libre de
Bruxelles, Brussels, Belgium; 5Hoffmann-La Roche Inc, Nutley, NJ, USA;
6Roche Products Limited, Welwyn Garden City, Herts, UK
OBJECTIVES: Oral ibandronate (ibandronic acid) is a bisphos-
phonate approved in the UK for treatment of bone metastases
from breast cancer. Administration of oral ibandronate once-
daily can be easily combined with oral hormonal therapy, saving
costs of iv bisphosphonate administration and monitoring. We
used cost-effectiveness (C/E) modelling to compare oral iban-
dronate with iv zoledronic acid or iv generic pamidronate in this
setting. METHODS: The model assumed a UK NHS perspective
with a duration of 14.3 months (expected average survival).
Patients were assumed to receive oral hormonal therapy for 53%
of their survival. Primary outcomes were direct Health Care costs
and QALYs. Resource use data for iv bisphosphonates came
from a published micro-costing study (validated through review
by a UK clinician); costs were calculated using a unit cost data-
base. Monthly drug acquisition costs were £195 for oral iban-
dronate and iv zoledronic acid, and £165 for iv generic
pamidronate. The cost of managing skeletal-related events
(SREs) came from a published study. Renal adverse events with
monitoring and treatment costs were assumed for zoledonic acid.
Efﬁcacy was calculated as the relative risk reduction (RR) of
SREs; utility scores were applied to time with/without an SRE
(SRE duration assumed 1 month). RESULTS: The projected total
cost was £297 less/patient with oral ibandronate than with zole-
dronic acid, and £1087 less than with generic pamidronate. Oral
ibandronate led to a gain of 0.02 QALYs (due to SRE RR and
bone pain relief), making it the economically dominant treatment
option. For completeness, C/E results for iv ibandronate will also
be presented, demonstrating C/E. CONCLUSIONS: This study
demonstrated the use of C/E modelling to compare oral versus
iv bisphosphonates using published data validated by expert clin-
ician review. Oral ibandronate was found to be cost-effective for
the management of bone metastases from breast cancer in
patients receiving oral hormonal therapy.
PCN9
A TIME-IN-MOTION STUDY OF ORAL IBANDRONATE VERSUS
IV ZOLEDRONIC ACID FOR THE TREATMENT OF METASTATIC
BONE DISEASE IN BREAST CANCER PATIENTS IN THE UK
Wardley A1, Body JJ2, Neary M3, Lewis G4
1Christie Hospital, Manchester, UK; 2Université Libre de Bruxelles,
Brussels, Belgium; 3Hoffmann-La Roche Inc, Nutley, NJ, USA; 4Roche
Products Limited, Welwyn Garden City, Herts, UK
OBJECTIVES: Oral bisphosphonates should reduce medical
resource use versus iv infusions. A US study used time-in-motion
methods to assess resource use for iv zoledronic acid vs. iv
pamidronate (DesHarnais CL et al, Support Care Cancer 2001).
